APOLIPOPROTEIN ISOFORMS AND RETINAL DEGENERATION

载脂蛋白异构体和视网膜变性

基本信息

  • 批准号:
    7229831
  • 负责人:
  • 金额:
    $ 15.24万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-02-01 至 2008-07-15
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The long-range goal of this study is to understand the biology of apolipoproteins in the retina, particularly the mechanism by which specific apoE isoforms may exert (or lack) neuroprotective effects. The immediate goal of this 2-year exploratory project is to develop and characterize the requisite genetically altered mouse strains to pursue the long-range goal. ApoE is a protein involved in cholesterol metabolism and transport. In the brain, the apoES isoform is thought to be neuroprotective and to play an important role in recovery following CNS injury. In contrast, the apoE4 isoform is a risk factor for dementias, such as Alzheimer's disease. Paradoxically, the exact opposite trend seems to prevail in age-related macular degeneration (AMD), where apoE4 correlates with reduced incidence of disease. The reason for this paradox remains a mystery, and will require appropriate new model systems to elucidate the molecular mechanisms involved. As a first step toward that goal, we will develop novel mouse strains and assess whether apoE can modulate the severity and time course of hereditary retinal degeneration in an isoform-specific manner. Mutant mice harboring the rds (retinal degeneration slow) mutation and lacking the apoE gene will be cross-bred with mice that selectively express either the human apoES or apoE4 isoform. Genotype will be confirmed by PCR. ApoE expression will be assessed as a function of age using Western blot analysis and immunocytochemistry, in comparison with age-matched rds and non-transgenic (wild-type) control mice. Retinal degeneration will be assessed by light and electron microscopy; retinal function will be assessed by electroretinography (ERG). The clinical relevance of this study lies in the potential to modulate the expression of neuroprotective isoforms of apoE in the retina as a novel therapy to retard or ameliorate human retinal degenerations of various origins. As such, this project has the potential to impact several aspects of the NEI's mission: to help prevent and treat eye diseases and other disorders of vision; reduce visual impairment and blindness; improve the quality of life for people of all ages; and advance our knowledge of how the visual system functions in health and disease.
描述(由申请人提供):这项研究的远距离目标是了解视网膜中载脂蛋白的生物学,尤其是特定的APOE同工型可能发挥(或缺乏)神经保护作用的机制。这个为期两年的探索项目的直接目标是开发和表征所需的遗传改变的小鼠菌株以追求远距离目标。 APOE是一种参与胆固醇代谢和运输的蛋白质。在大脑中,顶座同工型被认为是神经保护作用,并且在CNS损伤后恢复中起重要作用。相反,APOE4同工型是痴呆症的危险因素,例如阿尔茨海默氏病。矛盾的是,与年龄相关的黄斑变性(AMD)似乎完全相反的趋势,其中APOE4与疾病发病率降低相关。这种悖论的原因仍然是一个谜,将需要适当的新模型系统来阐明所涉及的分子机制。作为朝着该目标的第一步,我们将开发新型的小鼠菌株,并评估APOE是否可以以同工型特异性方式调节遗传性视网膜变性的严重性和时间过程。带有RDS(视网膜变性慢)突变和缺乏APOE基因的突变小鼠将与小鼠杂交,这些小鼠有选择地表达人顶或ApoE4同工型。基因型将通过PCR确认。与年龄匹配的RD和非转基因(野生型)对照小鼠相比,使用Western印迹分析和免疫细胞化学的APOE表达将作为年龄的函数评估。视网膜变性将通过光和电子显微镜评估;视网膜功能将通过视网膜图(ERG)评估。这项研究的临床相关性在于可能调节视网膜中APOE的神经保护同工型的表达,作为一种延迟或改善各种起源的人类视网膜退化的新疗法。因此,该项目有可能影响NEI使命的几个方面:帮助预防和治疗眼病和其他视力疾病;减少视力障碍和失明;改善各个年龄段的人们的生活质量;并促进我们对视觉系统在健康和疾病中如何发挥作用的知识。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据

数据更新时间:2024-06-01

Steven J. Fliesler的其他基金

Cholesterol homeostasis in the vertebrate retina
脊椎动物视网膜中的胆固醇稳态
  • 批准号:
    10580969
    10580969
  • 财政年份:
    2023
  • 资助金额:
    $ 15.24万
    $ 15.24万
  • 项目类别:
BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
  • 批准号:
    10512064
    10512064
  • 财政年份:
    2021
  • 资助金额:
    $ 15.24万
    $ 15.24万
  • 项目类别:
BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
  • 批准号:
    10365821
    10365821
  • 财政年份:
    2021
  • 资助金额:
    $ 15.24万
    $ 15.24万
  • 项目类别:
Development and characterization of mouse models of RP59 DHDDS deficiency
RP59 DHDDS 缺陷小鼠模型的开发和表征
  • 批准号:
    10200065
    10200065
  • 财政年份:
    2018
  • 资助金额:
    $ 15.24万
    $ 15.24万
  • 项目类别:
Ocular Sequelae and Intervention in a Rat Model of Blast Overpressure Polytrauma
爆炸超压多发伤大鼠模型的眼部后遗症及干预
  • 批准号:
    8819205
    8819205
  • 财政年份:
    2015
  • 资助金额:
    $ 15.24万
    $ 15.24万
  • 项目类别:
Ocular Sequelae and Intervention in a Rat Model of Blast Overpressure Polytrauma
爆炸超压多发伤大鼠模型的眼部后遗症及干预
  • 批准号:
    10082421
    10082421
  • 财政年份:
    2015
  • 资助金额:
    $ 15.24万
    $ 15.24万
  • 项目类别:
Ocular Sequelae and Intervention in a Rat Model of Blast Overpressure Polytrauma
爆炸超压多发伤大鼠模型的眼部后遗症及干预
  • 批准号:
    10735867
    10735867
  • 财政年份:
    2015
  • 资助金额:
    $ 15.24万
    $ 15.24万
  • 项目类别:
Ocular Sequelae and Intervention in a Rat Model of Blast Overpressure Polytrauma
爆炸超压多发伤大鼠模型的眼部后遗症及干预
  • 批准号:
    10361397
    10361397
  • 财政年份:
    2015
  • 资助金额:
    $ 15.24万
    $ 15.24万
  • 项目类别:
APOLIPOPROTEIN ISOFORMS AND RETINAL DEGENERATION
载脂蛋白异构体和视网膜变性
  • 批准号:
    7014983
    7014983
  • 财政年份:
    2006
  • 资助金额:
    $ 15.24万
    $ 15.24万
  • 项目类别:
APOLIPOPROTEIN ISOFORMS AND RETINAL DEGENERATION
载脂蛋白异构体和视网膜变性
  • 批准号:
    7683534
    7683534
  • 财政年份:
    2006
  • 资助金额:
    $ 15.24万
    $ 15.24万
  • 项目类别:

相似国自然基金

PGF突变介导的周细胞与内皮细胞crosstalk在湿性年龄相关性黄斑变性中的作用及机制研究
  • 批准号:
    82000898
  • 批准年份:
    2020
  • 资助金额:
    24 万元
  • 项目类别:
    青年科学基金项目
组织病理结构与临床检查对照观察在指导渗出性年龄相关性黄斑变性诊治中的意义研究
  • 批准号:
    81400409
  • 批准年份:
    2014
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
基于多模态医学影像技术的湿性年龄相关性黄斑变性诊断与分析
  • 批准号:
    81371629
  • 批准年份:
    2013
  • 资助金额:
    75.0 万元
  • 项目类别:
    面上项目

相似海外基金

Novel Polymer-antibody Conjugates as Long-acting Therapeutics for Ocular Diseases
新型聚合物-抗体缀合物作为眼部疾病的长效治疗药物
  • 批准号:
    10760186
    10760186
  • 财政年份:
    2023
  • 资助金额:
    $ 15.24万
    $ 15.24万
  • 项目类别:
Developing a novel disease-targeted anti-angiogenic therapy for CNV
开发针对 CNV 的新型疾病靶向抗血管生成疗法
  • 批准号:
    10726508
    10726508
  • 财政年份:
    2023
  • 资助金额:
    $ 15.24万
    $ 15.24万
  • 项目类别:
Project 1 - Molecular structure and function
项目1——分子结构与功能
  • 批准号:
    10628928
    10628928
  • 财政年份:
    2023
  • 资助金额:
    $ 15.24万
    $ 15.24万
  • 项目类别:
Deciphering the role of mitochondrial/autophagy dysfunction in regulating inflammatory processes during AMD pathogenesis
破译线粒体/自噬功能障碍在 AMD 发病机制中调节炎症过程中的作用
  • 批准号:
    10664118
    10664118
  • 财政年份:
    2023
  • 资助金额:
    $ 15.24万
    $ 15.24万
  • 项目类别:
Mitochondrial-Targeted Therapy for Macular Degeneration
线粒体靶向治疗黄斑变性
  • 批准号:
    10602150
    10602150
  • 财政年份:
    2023
  • 资助金额:
    $ 15.24万
    $ 15.24万
  • 项目类别: